Atorvastatin 20mg
ApprovedRecruiting 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Cerebrovascular Event
Conditions
Cerebrovascular Event, Stent Stenosis, Ischemic Stroke, Hemorrhagic Stroke, Stent Thrombosis, Death, Brain, Endothelial Dysfunction
Trial Timeline
Jul 30, 2024 → Dec 31, 2027
NCT ID
NCT06308952About Atorvastatin 20mg
Atorvastatin 20mg is a approved stage product being developed by Brain Biotech for Cerebrovascular Event. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06308952. Target conditions include Cerebrovascular Event, Stent Stenosis, Ischemic Stroke.
What happened to similar drugs?
4 of 6 similar drugs in Cerebrovascular Event were approved
Approved (4) Terminated (1) Active (1)
Hype Score Breakdown
Clinical
20
Activity
15
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06308952 | Approved | Recruiting |
Competing Products
14 competing products in Cerebrovascular Event
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| YM872 (zonampanel) | Astellas Pharma | Phase 2 | 35 |
| donepezil hcl | Eisai | Phase 3 | 40 |
| Donepezil hydrochloride + Donepezil matching placebo + Donepezil hydrochloride | Eisai | Approved | 43 |
| ONO-2506 | Ono Pharmaceutical | Phase 2/3 | 30 |
| Abciximab | Eli Lilly | Phase 3 | 32 |
| atomoxetine + Stimulants | Eli Lilly | Pre-clinical | 26 |
| ticagrelor + ASA + Placebo+ASA | AstraZeneca | Approved | 43 |
| Valsartan | Novartis | Pre-clinical | 18 |
| Atorvastatin | Pfizer | Approved | 43 |
| Rivaroxaban | Bayer | Pre-clinical | 19 |
| Darolutamide (BAY1841788) + Enzalutamide | Bayer | Phase 1 | 26 |
| Botulinum toxin type A + Placebo | Ipsen | Approved | 40 |
| Autologous bone marrow mononuclear cell transplantation | Brain Biotech | Phase 1 | 11 |
| Roflumilast Oral Tablet | Brain Biotech | Phase 2 | 25 |